News

Medical advice was sought on the fifth day of symptoms, and by this time, the child was improving clinically.

The photos in this case were taken soon after the painful and red papules appeared.

Among a low-income and racially/ethnically diverse sample of caregiver child dyads, text intervention was effective for toothbrushing, preventive dentist visits, and more.

Findings support continued caution in the use of glucocorticoids among pregnant people.

The use of pulse oximetry screening for asymptomatic newborns at or around 24 hours of life helps identify at-risk infants.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Russell Libby, MD, FAAP highlights some key benefits of roflumilast 0.15%, approved in 2024 to treat AD in patients aged 6 years and older.

Kick off the new year with 8 parenting goals: update vaccines, build healthy habits, enjoy outdoor time, read daily, and prioritize mental health.

Contemporary Pediatrics' editorial advisory member Russell Libby, MD, FAAP, highlights 2024 FDA approval of epinephrine nasal spray (Neffy) in this video interview.

Needle-free treatments, such as Neffy and FluMist, offer promising alternatives for children and adults with needle phobia, ensuring access to critical care.

Discover expert tips for safe and balanced tech use this holiday season with parental controls, privacy guidance, and social media insights.

Can you guess what condition Tiny Tim had?

Pregnant women infected with avian influenza face a 90% maternal and 86% infant mortality rate, underscoring the urgent need for pandemic preparedness and protection strategies.

This week the panel weighs in on monoclonal antibodies in this patient population as well as important overall takeaways about COVID-19 therapies.

The indication is for patients 12 years and older hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The expanded indication is approved to reduce excess body weight and maintain reduction long-term in children 2 years and up with obesity due to BBS, POMC, or LEPR deficiency.

"Tapinarof comes in with that mixture of the short-term studies and longer-term studies intermittently, giving us a nice, effective alternative non-steroid for eczema across the ages."

The primary endpoint was non-inferiority in HbA1c levels after 26 weeks.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, highlights the latest issue of Contemporary Pediatrics.

"Our findings support the recommendation of a healthy diet based on the current guidelines (as measured by the HEI) during pregnancy, since it may reduce patterns of infant growth outside reference ranges."

Nathan Kuppermann, MD, MPH, explains the different quartiles of the pediatric emergency department readiness scale, and why the top tier is so crucial for pediatric patients.

With the federal agency's decision, remestemcel-L-rknd has become the first FDA-approved mesenchymal stromal cell therapy.

This week, our experts weigh in on treatments not specifically indicated for COVID-19 treatment, including metformin, and concerns around using medications in this way.

Can you diagnose this healthy, 8.2-lb girl with lesions primarily on her lower lip but also her upper lip, cheeks, and nasolabial folds?

From new topical dermatology treatments for atopic dermatitis to the first nasal spray to treat type 1 allergic reactions, these are our top FDA approvals of 2024.

Currently, golimumab is approved in adults with moderately to severely active ulcerative colitis.

Greg Forlenza, MD, offers practical advise for primary care providers regarding continuous glucose monitors and automatic insulin delivery systems.